You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

CLINICAL TRIALS PROFILE FOR DEXONE 4


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Dexone 4

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004228 ↗ Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed National Cancer Institute (NCI) Phase 3 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗ Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma Completed Children's Oncology Group Phase 3 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00025259 ↗ Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed National Cancer Institute (NCI) Phase 3 2002-09-01 This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dexone 4

Condition Name

Condition Name for Dexone 4
Intervention Trials
Recurrent Plasma Cell Myeloma 34
Refractory Plasma Cell Myeloma 29
Acute Lymphoblastic Leukemia 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dexone 4
Intervention Trials
Multiple Myeloma 61
Neoplasms, Plasma Cell 60
Leukemia 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dexone 4

Trials by Country

Trials by Country for Dexone 4
Location Trials
Canada 140
Australia 64
New Zealand 28
Puerto Rico 15
Switzerland 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dexone 4
Location Trials
Texas 64
Minnesota 61
California 50
Michigan 44
Florida 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dexone 4

Clinical Trial Phase

Clinical Trial Phase for Dexone 4
Clinical Trial Phase Trials
Phase 4 2
Phase 3 26
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dexone 4
Clinical Trial Phase Trials
Recruiting 48
Completed 31
Active, not recruiting 30
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dexone 4

Sponsor Name

Sponsor Name for Dexone 4
Sponsor Trials
National Cancer Institute (NCI) 126
M.D. Anderson Cancer Center 30
Mayo Clinic 24
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dexone 4
Sponsor Trials
NIH 127
Other 126
Industry 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Dexamethasone: Clinical Trials, Market Analysis, and Projections

Introduction to Dexamethasone

Dexamethasone is a potent anti-inflammatory synthetic adrenal corticosteroid widely used to treat various inflammatory conditions, including allergic disorders, skin diseases, adrenal problems, arthritis, severe allergies, asthma, blood or bone marrow problems, and more. Its efficacy and broad application have made it a crucial drug in modern medicine.

Clinical Trials Update

COVID-19 Treatment

A significant clinical trial has investigated the efficacy of high-dose versus low-dose dexamethasone in hospitalized COVID-19 patients requiring oxygen therapy. This randomized, open-label, controlled trial involved 200 patients, with 102 receiving low-dose dexamethasone (6 mg once daily for 10 days) and 98 receiving high-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days)[1].

  • Primary Outcome: The trial found that high-dose dexamethasone reduced clinical worsening within 11 days after randomization compared to the low-dose group. Specifically, 31.4% of patients in the low-dose group and 16.3% in the high-dose group showed clinical worsening.
  • Secondary Outcomes: There was no significant difference in 28-day mortality or time to recovery between the two groups. The clinical status at days 5, 11, 14, and 28 also showed no significant differences.

Oncology

In the realm of oncology, dexamethasone is often used in combination with other therapies. For example, C4 Therapeutics is conducting a Phase 1/2 clinical trial for CFT7455, a novel degrader targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas. This trial includes a combination arm where CFT7455 is used with dexamethasone in patients with relapsed or refractory multiple myeloma[3].

Market Analysis

Market Size and Forecast

The global dexamethasone market is experiencing significant growth, driven primarily by its increased use as a lifesaving therapy for severely ill COVID-19 patients. Here are some key market insights:

  • Market Size: The market is projected to reach USD 4,634.01 million by 2028, growing at a CAGR of 6.65% from 2021 to 2028[2].
  • Growth Drivers: The rapid adoption of dexamethasone for COVID-19 treatment, along with its use in various inflammatory conditions and diseases such as cancer, allergic disorders, and skin conditions, are major growth drivers[5].

Geographic Distribution

The market is geographically diverse, with different regions contributing significantly:

  • North America: Leads the dexamethasone market due to the high prevalence of diseases and the rapid rise in COVID-19 cases[2].
  • Asia-Pacific: Expected to expand at a significant growth rate due to the rising prevalence of viral disease outbreaks and the strong presence of major manufacturers in this region[2].

End User Segmentation

The market is segmented based on end users, with hospitals holding the majority of the market share:

  • Hospitals: High hospital admissions for various diseases, including COVID-19, contribute to the dominance of this segment[5].
  • Clinics, Pharmacy & Drug Stores, and Online Pharmacies: These segments also play important roles, especially during the pandemic when access to healthcare services was critical.

Market Projections

Future Growth

The global dexamethasone market is expected to continue its upward trend due to several factors:

  • Increased Incidence of Inflammatory Ailments: The rising incidence of various inflammatory conditions will fuel the expansion of the dexamethasone market[5].
  • Research and Development: Robust investment in research and development is expected to contribute to the market's growth over the forecast period[2].
  • Pandemic Impact: The high impact of pandemics, such as COVID-19, and the authorization for emergency use of dexamethasone will continue to drive market growth[5].

Competitive Landscape

The competitive landscape of the dexamethasone market is characterized by several key players and strategies:

  • Company Market Ranking: Major pharmaceutical companies are competing based on their market share, product portfolio, and innovation in delivery mechanisms[5].
  • Key Development Strategies: Companies are focusing on expanding their product lines, investing in research and development, and enhancing their distribution networks to capture a larger market share[5].

Anti-inflammatory and Immunosuppressant Effects

Dexamethasone's anti-inflammatory and immunosuppressant properties make it a versatile drug:

  • Inflammatory Conditions: It is effective in treating various inflammatory conditions such as arthritis, lupus, and psoriasis[5].
  • Respiratory Distress Syndrome: Dexamethasone has been used to manage respiratory distress syndrome, particularly in COVID-19 patients[5].

COVID-19 and Dexamethasone

The COVID-19 pandemic has significantly impacted the demand for dexamethasone:

"Dexamethasone reduced 28-day mortality among patients hospitalized with Covid-19 who were receiving either invasive mechanical ventilation or oxygen alone at the time of randomization, but not among those who were receiving no respiratory support."[5]

This has led to a surge in its use and subsequent market growth.

Conclusion

Dexamethasone is a critical drug with a wide range of applications, from treating inflammatory conditions to being a lifesaving therapy for COVID-19 patients. Clinical trials have shown its efficacy in reducing clinical worsening in COVID-19 patients and its potential in oncology when combined with other therapies. The market for dexamethasone is projected to grow significantly, driven by its increased use in various medical conditions and the ongoing impact of pandemics.

Key Takeaways

  • Clinical Efficacy: High-dose dexamethasone reduces clinical worsening in hospitalized COVID-19 patients.
  • Market Growth: The global dexamethasone market is expected to reach USD 4,634.01 million by 2028.
  • Geographic Distribution: North America and Asia-Pacific are key regions driving market growth.
  • End User Segmentation: Hospitals dominate the market due to high admissions for various diseases.
  • Future Growth Drivers: Increased incidence of inflammatory ailments, robust R&D, and pandemic impacts.

FAQs

What is the primary use of dexamethasone in COVID-19 treatment?

Dexamethasone is primarily used to reduce clinical worsening and mortality in hospitalized COVID-19 patients requiring oxygen therapy.

How does the dosage of dexamethasone impact its efficacy in COVID-19 patients?

High-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days) has been shown to reduce clinical worsening within 11 days after randomization compared to low-dose dexamethasone[1].

What are the key growth drivers for the global dexamethasone market?

The key growth drivers include the increased use of dexamethasone as a lifesaving therapy for COVID-19, rising incidence of inflammatory ailments, and robust investment in research and development[2][5].

Which regions are expected to drive the growth of the dexamethasone market?

North America and Asia-Pacific are expected to drive significant growth due to the high prevalence of diseases and the presence of major manufacturers[2].

How is dexamethasone used in oncology?

Dexamethasone is often used in combination with other therapies in oncology, such as in the treatment of multiple myeloma and non-Hodgkin’s lymphomas, where it is combined with novel degraders like CFT7455[3].

Sources

  1. Effect of high versus low dose of dexamethasone on clinical worsening in hospitalised COVID-19 patients needing oxygen therapy: a randomised, open-label, controlled trial. PubMed.
  2. Global Dexamethasone Market – Industry Trends and Forecast to 2028. Data Bridge Market Research.
  3. C4 Therapeutics, Inc. - Advancing Targeted Protein Degradation Science. C4 Therapeutics.
  4. Daratumumab Plus Standard Therapy for Multiple Myeloma. National Cancer Institute.
  5. Dexamethasone Market Size, Share, Trends, Opportunities & Forecast. Verified Market Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.